Last reviewed · How we verify
NCT03073434
Pregnancy Outcomes in Renal Transplant Recipients
trial in Renal Transplant in 17 participants. Status unknown.
1 March 2022
Quick facts
| Lead sponsor | Unity Health Toronto |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 17 |
| Start date | 1 March 2016 |
| Primary completion | 1 March 2022 |
| Estimated completion | 1 March 2022 |
Conditions studied
- Renal Transplant — all drugs for Renal Transplant →
Sponsor
Unity Health Toronto — full company profile →
Who can join
Eligibility, female only, with Renal Transplant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective study involving all patients with a history of renal transplant that attended antenatal clinics at various Toronto hospitals and subsequently delivered between January 2000 and December 2014. The purpose of this study is to describe the incidence of adverse pregnancy-and transplant-related outcomes, and report placental ultrasound and placental pathology findings in renal transplant recipients with contemporary standards of care in Toronto. This study also seeks to determine whether factors such as maternal age, transplant-to-pregnancy interval, hypertension, diabetes mellitus, treatment regimens, and the primary cause for renal failure are associated with higher risk of adverse pregnancy outcomes in renal transplant recipients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03073434
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Transplant
Currently open trials in the same condition.
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT07392996 — Does Early Postoperative Fluid Management Affect Functional Delayed Graft Function After Living Donor Kidney Transplanta · active not recruiting
- NCT07181096 — Frailty Among Renal Transplant Recipients and Relation to Chronic Allograft Dysfunction · NA · recruiting
- NCT06288152 — Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation · NA · recruiting
- NCT06025240 — Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients · recruiting
Other Unity Health Toronto trials
Trials by the same sponsor.
- NCT07507409 — Innovative Sternal Closure Techniques: Evaluating STRATAFIX™ and DERMABOND™ for Reduced Complications in CABG Patients · Phase 4 · not yet recruiting
- NCT07455487 — First Appendectomy Using Revolve Surgical Robotic Arm · NA · not yet recruiting
- NCT07301632 — Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial · Phase 2 · recruiting
- NCT07314905 — Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) · Phase 3 · not yet recruiting
- NCT06571916 — Brief Skills for Safer Living (Brief-SfSL) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03073434 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Unity Health Toronto
- Last refreshed: 29 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03073434.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing